GP Strategies Announces FDA Approval of Valera Implant.

NEW YORK -- GP Strategies Corporation (NYSE:GPX), a global provider of training, e-Learning solutions, management consulting, engineering, and simulation services, today announced that Valera Pharmaceuticals has received Food and Drug Administration approval for the marketing of Vantas(TM), Valera's long-acting implant, indicated for the palliative treatment of advanced prostate cancer.

Utilizing Valera's Hydron Implant technology, Vantas(TM) has been designed for the continuous 12-month administration of histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH). LHRH agonists have become a mainstay in treating locally advanced and metastatic prostate cancer, with the U.S. market for such therapies representing over $1 billion in annual sales. However, this market has been dominated by four-month and shorter duration depot injections or implants.

GP Strategies owns approximately 15.3% of Valera on a fully diluted basis (18.4% if an option expiring October 28, 2004 is exercised). In connection with the previously announced spin off of National Patent Development Corporation by GP Strategies, GP Strategies will make a capital contribution of its Valera investment to National Patent Development.

Jerome I. Feldman, the Chairman and Chief Executive Officer of GP Strategies, stated "I take special pride in FDA approval of a technology which GP Strategies has nurtured for 15 years. I am grateful that David Tierney and his management team at Valera have been able to achieve this milestone, and I am fully confident of their ability to commercialize this product and guide Valera in its transition to a specialty pharma company."

GP Strategies, whose principal operating subsidiaries are General Physics Corporation and GSE Systems Inc., is a NYSE listed company (GPX). General Physics and GSE Systems are global providers of training, e-Learning solutions, management consulting, engineering and simulation services, improving the effectiveness of organizations by customizing solutions to meet the specific needs of clients. Clients include Fortune 500 companies, manufacturing, process and energy industries, and other commercial and government customers. Additional information about GP Strategies may be found at www.gpstrategies.com and about General Physics at www.gpworldwide.com.

The forward-looking statements contained herein reflect GP Strategies' management's current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of GP Strategies, including, but not limited to the risks and uncertainties detailed in GP Strategies' periodic reports and registration statements filed with the Securities and Exchange Commission.